BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

Spherix Global Insights’ Q1 2026 update of RealTime Dynamix™: Multiple Myeloma findings point to a clear inflection in treatment strategy, as physicians grow increasingly confident in CAR-T therapy ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

CAR T-cells are a type of modified T cells from the immune system, designed to recognize and eliminate cancerous cells, a more selective approach compared to the general killing of infectious cells ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Allogene Therapeutics, a leading biotechnology company, has made significant strides in the field of cell therapy, ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.